Skip to main content

Chemotherapy-induced Neutropenia

6
Pipeline Programs
12
Companies
23
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Biocad
BiocadRussia - St. Petersburg
2 programs
1
1
Empegfilrastim 6 mgPhase 31 trial
empegfilrastimPhase 21 trial
Active Trials
NCT01569087Completed60Est. Feb 2013
NCT02104830Completed135Est. Oct 2014
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
Long-acting granulocyte colony stimulating factorPhase 31 trial
Active Trials
NCT04101760Unknown200Est. Oct 2020
Amoytop Biotech
Amoytop BiotechChina - Xiamen
1 program
1
filgrastimPhase 34 trials
Active Trials
NCT07384936Not Yet Recruiting100Est. Dec 2027
NCT06924385Completed18Est. Jan 2026
NCT06893796Completed18Est. May 2025
+1 more trials
Enzychem Lifesciences
2 programs
2
EC-18Phase 11 trial
EC-18Phase 11 trial
Active Trials
NCT02532712Completed64Est. Dec 2015
NCT02496143Completed33Est. Dec 2015
BeyondSpring Pharmaceuticals
4 programs
PlinabulinPHASE_21 trial
PlinabulinPHASE_21 trial
PegfilgrastimPHASE_31 trial
PlinabulinPHASE_31 trial
Active Trials
NCT04345900Completed55Est. Apr 2018
NCT04227990Completed115Est. Jan 2019
NCT03294577Unknown221Est. Sep 2025
+1 more trials
T-Therapeutics
T-TherapeuticsUK - Cambridge
3 programs
GW003PHASE_11 trial
GW003PHASE_11 trial
Pegylated Recombinant Human G-CSFPHASE_11 trial
Active Trials
NCT02643901CompletedEst. Oct 2016
NCT02156388CompletedEst. Dec 2015
NCT02725606UnknownEst. Sep 2017
Teva
TevaIsrael - Petach Tikva
2 programs
BalugrastimPHASE_2_31 trial
NeugraninPHASE_31 trial
Active Trials
NCT00837265Completed334Est. Jun 2009
NCT01126190Completed381Est. Feb 2012
Pfizer
PfizerNEW YORK, NY
1 program
Nivestim®N/A1 trial
Active Trials
NCT02454530Terminated1,160Est. Jan 2017
Cinnagen
CinnagenIran - Tehran
1 program
Peg-filgrastimN/A1 trial
Active Trials
NCT04460079Completed654Est. Sep 2019
Parexel
ParexelMA - Boston
1 program
Maxy-G34PHASE_21 trial
Active Trials
NCT00501332Unknown30
Myelo Therapeutics
Myelo TherapeuticsGermany - Berlin
1 program
Myelo001PHASE_21 trial
Active Trials
NCT02692742Completed137Est. Nov 2017
Novartis
NovartisBASEL, Switzerland
1 program
LA-EP2006PHASE_31 trial
Active Trials
NCT01516736Completed308Est. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
BeyondSpring PharmaceuticalsPegfilgrastim
UNION therapeuticsLong-acting granulocyte colony stimulating factor
BeyondSpring PharmaceuticalsPlinabulin
BiocadEmpegfilrastim 6 mg
NovartisLA-EP2006
TevaNeugranin
TevaBalugrastim
BeyondSpring PharmaceuticalsPlinabulin
BeyondSpring PharmaceuticalsPlinabulin
Myelo TherapeuticsMyelo001
Biocadempegfilrastim
ParexelMaxy-G34
Amoytop Biotechfilgrastim
Amoytop Biotechfilgrastim
T-TherapeuticsPegylated Recombinant Human G-CSF

Showing 15 of 23 trials with date data

Clinical Trials (23)

Total enrollment: 4,158 patients across 23 trials

NCT03294577BeyondSpring PharmaceuticalsPegfilgrastim

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Start: Oct 2019Est. completion: Sep 2025221 patients
Phase 3Unknown
NCT04101760UNION therapeuticsLong-acting granulocyte colony stimulating factor

Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer

Start: Oct 2019Est. completion: Oct 2020200 patients
Phase 3Unknown
NCT03102606BeyondSpring PharmaceuticalsPlinabulin

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Start: May 2018Est. completion: Feb 2021105 patients
Phase 3Completed
NCT02104830BiocadEmpegfilrastim 6 mg

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Start: Sep 2013Est. completion: Oct 2014135 patients
Phase 3Completed
NCT01516736NovartisLA-EP2006

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Start: Mar 2012Est. completion: Dec 2013308 patients
Phase 3Completed
NCT01126190TevaNeugranin

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Start: Jun 2010Est. completion: Feb 2012381 patients
Phase 3Completed
NCT00837265TevaBalugrastim

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Start: Aug 2008Est. completion: Jun 2009334 patients
Phase 2/3Completed
NCT04227990BeyondSpring PharmaceuticalsPlinabulin

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Start: Nov 2017Est. completion: Jan 2019115 patients
Phase 2Completed
NCT04345900BeyondSpring PharmaceuticalsPlinabulin

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Start: Apr 2017Est. completion: Apr 201855 patients
Phase 2Completed
NCT02692742Myelo TherapeuticsMyelo001

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

Start: Mar 2016Est. completion: Nov 2017137 patients
Phase 2Completed
NCT01569087Biocadempegfilrastim

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Start: May 2012Est. completion: Feb 201360 patients
Phase 2Completed
NCT00501332ParexelMaxy-G34

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Start: Jul 200730 patients
Phase 2Unknown
NCT06924385Amoytop Biotechfilgrastim

Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing

Start: Apr 2025Est. completion: Jan 202618 patients
Phase 1Completed
NCT06893796Amoytop Biotechfilgrastim

Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females

Start: Mar 2025Est. completion: May 202518 patients
Phase 1Completed
NCT02725606T-TherapeuticsPegylated Recombinant Human G-CSF

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Start: Mar 2016Est. completion: Sep 2017
Phase 1Unknown
NCT02643901T-TherapeuticsGW003

Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects

Start: Sep 2015Est. completion: Oct 2016
Phase 1Completed
NCT02496143Enzychem LifesciencesEC-18

A Safety and PK Study of EC-18 in Healthy Subjects

Start: Jul 2015Est. completion: Dec 201533 patients
Phase 1Completed
NCT02532712Enzychem LifesciencesEC-18

Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

Start: Mar 2015Est. completion: Dec 201564 patients
Phase 1Completed
NCT02156388T-TherapeuticsGW003

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

Start: Aug 2013Est. completion: Dec 2015
Phase 1Completed
NCT01238562Amoytop Biotechfilgrastim

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of YPEG-Filgrastim in Chemotherapy Patients

Start: Apr 2010Est. completion: Nov 201130 patients
Phase 1Completed
NCT07384936Amoytop Biotechfilgrastim

Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia

Start: Jan 2026Est. completion: Dec 2027100 patients
N/ANot Yet Recruiting
NCT04460079CinnagenPeg-filgrastim

Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN

Start: Mar 2016Est. completion: Sep 2019654 patients
N/ACompleted
NCT02454530PfizerNivestim®

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

Start: Sep 2014Est. completion: Jan 20171,160 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.